Nancy Pelosi is negotiating with the White Housed on far-reaching drug-pricing legislation and Medicare reforms. Now is the time to try Inside Health Policy.

Sign up for 30 days of no-obligation access for all the essential news during this critical time -- you'll be able to choose one of our online services as part of your trial: Inside CMS, FDA Week, Health Exchange Alert or Inside Drug Pricing.


Top Story

White House Wants Inflation, Medicaid Drug Rebates In Budget Deal

The White House asked Democrats late Thursday (July 19) to include in a budget deal Senate Democratic drug-pricing policies that would save the government $115 billion, multiple sources say.

Four Pharma Executives Met With White House Officials Thursday

Latest News

The Trump administration told a federal appeals court Thursday (July 18) that states should be able to continue testing Medicaid work requirements even as the administration acknowledged problems in how Arkansas initially implemented its first-in-the-nation work requirement program.

House lawmakers want FDA to expedite its review of drug substances nominated for inclusion on the agency's list of bulk substances that can be compounded based on a clinical need.

Trial lawyers and beneficiary advocates say CMS’ decision to scrap its ban on nursing homes using pre-dispute, binding arbitration will deny beneficiaries access to the courts when a problem arises, even though the agency says nursing homes can’t force beneficiaries to agree to pre-dispute arbitration as a condition of receiving care.

CMS can accelerate the work of state Medicaid programs seeking to tackle social determinants of health by providing guidance and templates for how to obtain Medicaid waivers, providing a thorough evaluation of existing demonstrations to devise best practices, and facilitating information-sharing between states, according to Medicaid advocates.

Sen. Bill Cassidy (R-LA) said that the arbitration backstop plan the House added to its surprise billing policy could lead to artificially inflated rates, and he is lobbying the Senate to add a different arbitration approach to its surprise billing measure.

Patients’ groups and some Medicaid policy experts are urging the Trump administration to backtrack from a planned CMS guidance letter that is expected to invite states to use 1115 waivers to accept federal Medicaid money through block grants.

House lawmakers have reintroduced a bill that would require FDA, in consultation with the National Institute on Drug Abuse (NIDA), to issue guidelines on the production of marijuana as part of the legislation’s larger goal to amend the Controlled Substances Act to make marijuana accessible to researchers for medical purposes.

FDA Principal Deputy Commissioner Amy Abernethy will discuss hemp production during a July 25 Senate agriculture committee hearing, the committee announced Wednesday (July 17).

The National Milk Producers Federation (NMPF) complained to FDA on Wednesday (July 17) that the agency has yet to resolve issues surrounding its standard of identity for milk, namely whether plant-based products should be called “milk.”

The House Energy & Commerce Committee added an arbitration backstop to its surprise billing legislation, making the House bill notably different from the Senate version, which could cause problems when the bill goes to conference.